EUVIMEDEUVIMED entdecken
Crossref

CD300A + CD8 + T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy

Peng Zhang, Wen-Xin Wang, Jing Li, Qiaolan Lv, Meng-Meng Zhu, You-Yuan Wang, Ming-Ju Zhou, Si-Yuan Chen, Yan-Mei Jiao, Xing Fan, Jin-Wen Song, Ruonan Xu und 5 weitere

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Peng Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Interferon-alpha, CD8-Positive T-Lymphocytes, Antiviral Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Beijing Nova Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Pegylated interferon‐alpha (PEG‐IFN‐α) is the first choice for achieving functional cure (FC) in chronic hepatitis B (CHB), but only about 30% of patients achieve this outcome within a defined treatment duration. Given the critical role of CD8 + T cells as antiviral effectors, we investigated their changes during FC to identify novel predictive markers of treatment efficacy.

Methods

We enrolled CHB patients with serum HBsAg levels < 3000 IU/mL in a discovery cohort and collected their peripheral blood mononuclear cells after PEG‐IFN‐α therapy. We used single‐cell transcriptome profiling coupled with T cell receptor (TCR) sequencing and flow cytometry to assess CD8 + T cell immune characteristics. Findings were validated longitudinally by flow cytometry in an independent cohort receiving PEG‐IFN‐α therapy.

Results

In FC patients, CD8 + T cell subsets exhibited distinct transcriptional profiles. c04 (Temra/Teff) and c06 (proliferating T) showed significant clonal expansion compared to non‐FC patients. CD300A expression was highly enriched in FC cells, correlating with cytotoxicity‐related gene signatures (e.g., GZMB , GNLY , PRF1 ). CD300A + CD8 + T cells demonstrated greater clonal expansion, enhanced antigen reactivity and a transcriptional network driven by TBX21 and EOMES , with enrichment of HBV‐specific CD8 + T cells. Longitudinal validation confirmed that baseline CD300A + CD8 + T cells, particularly non‐naive subsets, were associated with greater HBsAg decline and earlier FC, independent of baseline HBsAg levels.

Conclusions

CD300A + CD8 + T cells are enriched in patients achieving FC during PEG‐IFN‐α therapy, exhibiting robust clonal expansion, enhanced cytotoxicity and HBV antigen specificity. These cells may serve as potential biomarkers for treatment response to improve FC rates in CHB therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicInterferon-alphaCD8-Positive T-LymphocytesAntiviral AgentsPolyethylene GlycolsReceptors, ImmunologicHumansMaleFemaleAdultBiomarkersMiddle AgedTreatment OutcomeRecombinant ProteinsFlow CytometryHepatitis B Surface Antigens

Stichwörter der Autor:innen

CD300APEG‐IFN‐α therapybiomarkerchronic hepatitis Bfunctional cure

Substanzen

Interferon-alphaAntiviral AgentsBiomarkersPolyethylene GlycolsRecombinant ProteinsReceptors, Immunologicpeginterferon alfa-2aHepatitis B Surface Antigens

Autor:innen und Institutionen

  • The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Peking University 302 Clinical Medical School, National Clinical Research Center for Infectious Diseases, Beijing, Chin…

ORCID-Profile: Fu-Sheng Wang, Chao Zhang

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Beijing Nova Program
  • capital clinical diagnosis and treatment technology research and transformation application project

Zitieren

APA

Zhang, P., Wang, W. X., Li, J., Lv, Q., Zhu, M. M., Wang, Y. Y., Zhou, M. J., Chen, S. Y., Jiao, Y. M., Fan, X., Song, J. W., Xu, R., Zhen, C., Shi, M., Wang, F. S., Fu, J., & Zhang, C. (2025). CD300A + CD8 + T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70214

Vancouver

Zhang P, Wang WX, Li J, Lv Q, Zhu MM, Wang YY, et al. CD300A + CD8 + T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70214

BibTeX
@article{Zhang2025,
  author = {Zhang, Peng and Wang, Wen-Xin and Li, Jing and Lv, Qiaolan and Zhu, Meng-Meng and Wang, You-Yuan and Zhou, Ming-Ju and Chen, Si-Yuan and Jiao, Yan-Mei and Fan, Xing and Song, Jin-Wen and Xu, Ruonan and Zhen, Cheng and Shi, Ming and Wang, Fu-Sheng and Fu, Junliang and Zhang, Chao},
  title = {CD300A + CD8 + T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70214}
}
Kostenlos starten →